Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2020 20:00 ET | Source: Capstone Therapeutics

CAPSTONE THERAPEUTICS ANNOUNCES TRANSACTION WITH TOTALSTONE LLC

TEMPE, Ariz., March 27, 2020 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB: CAPS) (“the Company”) RECAPITALIZATION OF AND MERGER WITH TOTALSTONE LLC In March 2020, the Company entered into an...
May 07, 2018 09:00 ET | Source: Capstone Therapeutics

LipimetiX Development Announces Sub-License of Apo E Mimetic Peptide Platform to Anji Pharma, China

NATICK, Mass., May 07, 2018 (GLOBE NEWSWIRE) -- LipimetiX Development, Inc. (“LipimetiX” or “the Company”) announced today that Anji Pharmaceuticals, Inc. (“Anji Pharma”) has entered a licensing...
July 17, 2017 08:00 ET | Source: Capstone Therapeutics

Capstone Therapeutics Announces Transaction for Sale of Shares of Its Common Stock and Secured Loan

TEMPE, Ariz., July 17, 2017 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) announced today that on July 14, 2017, BP Peptides, LLC (“Brookstone”) purchased 13,500,000...
December 19, 2016 11:52 ET | Source: Capstone Therapeutics

Capstone Therapeutics Announces Profound, Rapid LDL Cholesterol Reduction in AEM-28-14 Primate Study

TEMPE, Ariz., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s drug development joint venture (“JV”)...
August 25, 2016 09:00 ET | Source: Capstone Therapeutics

Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc., Has Closed a Series B-1 Preferred Stock Offering

TEMPE, Ariz., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s drug development joint venture (“JV”)...
February 03, 2016 15:29 ET | Source: Capstone Therapeutics

Capstone Therapeutics Announces Existing Shareholder Decision Not to Extend Exclusive due Diligence Period

TEMPE, Ariz., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s 60% owned joint venture (“JV”) announced today...
December 15, 2015 16:15 ET | Source: Capstone Therapeutics

Capstone Therapeutics Announces Loan From Existing Shareholder for Exclusive Due Diligence Period

TEMPE, Ariz., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s 60% owned joint venture (“JV”) announced today...
October 14, 2015 09:00 ET | Source: Capstone Therapeutics

Capstone Therapeutics Announces Allowance of U.S. Patent for Treatment of Diabetes With Apo E Mimetic Peptides

TEMPE, Ariz., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Capstone Therapeutics, Inc. (OTCQB:CAPS) ("the Company") and its (60% owned) joint venture affiliate, LipimetiX Development, Inc. ("JV"), announced...
August 10, 2015 11:36 ET | Source: Capstone Therapeutics

Capstone Therapeutics Announces Second Quarter 2015 Financial Results and Operating Update Conference Call

TEMPE, Ariz., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS); (the "Company"), will hold a conference call and webcast on Thursday, August 13, 2015 at 4:30 pm EDT. The call may...
July 23, 2015 08:00 ET | Source: Capstone Therapeutics

Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides

TEMPE, Ariz., July 23, 2015 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company") and its joint venture affiliate, LipimetiX Development, Inc. ("JV"), announced today the...